Founded by serial entrepreneurs and seasoned investors.
We back ambitious software-driven and hardware-enabled startups solving real, challenging problems.
Initial check
Up to 3m PLN
Follow-on
Up to 5m PLN
Stage
Pre to early revenue
Geography
Poland / use funds in Poland
Must have
Ambitious, resourceful, and relentless – truly Hard2beat
We don’t invest in B2C, marketplaces, or generic SaaS.
Neuromedical has developed VGuard, a non-invasive vagus nerve stimulation system (tVNS) that has demonstrated significant improvements in cognitive function in Alzheimer’s patients in clinical trials.
Pikralida is developing PKL-021, a rediscovered small-molecule MMP inhibitor to provide acute neuroprotection after stroke and traumatic brain injury and to offer fast, field-ready treatment for venomous snakebites in humans and pets.
Ludus AI is developing a next-generation solution for the 3D game and visualization industry. The company focuses on simplifying the creation of high-quality content in Unreal Engine through the use of artificial intelligence.
We blend firsthand founder experience (scaling businesses to €14M+ ARR, multiple exits) with deep VC expertise (100+ investments). We quickly spot what matters and act fast.
Deep, hands-on advice on global sales, R&D, fundraising, and legal structuring – no fluff, no micromanaging. When things get tough, you’ll want us in your corner.
Access our local and international network of 250+ investors, angels, and industry partners. Whether you’re raising funds, closing deals, or hiring key roles – we connect you fast.
Veteran VC with 40+ pre-seed deals under his belt. Deep expertise in R&D-heavy startups, company-building, and fundraising strategy. Gets technical founders and what they need to thrive.
Former CVC scout connecting startups with corporates. Deep understanding of PoC design, enterprise integration, and tech commercialization. Based in Kraków, always exploring what’s next, especially in deep tech and enterprise.
December is when productivity usually flatlines – but European Deep Tech didn’t get the memo. While everyone else was eating chocolate for breakfast, VCs shoved ~$1.5B into startups rewriting physics, manufacturing, and biology, as the market keeps shifting hard from bits to atoms. Here’s what happened in December 2025.
Maciej Frankowicz przybliża słuchaczom rzeczywistość polskiego ekosystemu startupowego, koncentrując się na rynku venture capital. Celem rozmowy było uważne przyjrzenie się polskiemu rynkowi VC, podsumowanie wydarzeń z ostatnich miesięcy i ocena tempa odbudowy rynku oraz przedstawienie prognoz na nadchodzące miesiące.
In the fifth episode of the Hard2beat Podcast, we sit down with James “Jimmy” Buchheim — serial entrepreneur, founder of multiple deep-tech companies in the US and Europe, and now CEO of DefendEye: a tube-launched autonomous drone built for first responders, tactical units and critical-incident teams.
Pikralida is developing PKL-021, a rediscovered small-molecule MMP inhibitor that has completed Phase I and is now being advanced into Phase II-ready programs to provide acute neuroprotection after stroke and traumatic brain injury and to offer fast, field-ready treatment for venomous snakebites in humans and pets.
Polski startup biotechnologiczny Pikralida otrzymał 12,5 mln zł w nowej rundzie inwestycyjnej, w której udział wzięły fundusze Hard2Beat, iif.vc, N50/Manawa, Altamira VC oraz grupa aniołów biznesu. Środki pozwolą firmie przyspieszyć prace nad testami klinicznymi, rejestracją leków oraz wprowadzeniem pierwszego produktu na rynek w latach 2027–2028.
A VC take on the photonic chip market, from Moore’s Law limits to AI data center power use – and where ambitious founders can build enduring companies.
